[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ebv-tnk-lpd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ebv-tnk-lpd":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100595246","phase-4-improved-myeloablative-allogeneic-hematopoietic-stem-cell-transplantation-protocol-for-the-treatment-of-epstein-barr-virus-tnk-lymphoproliferative-disease-ebv-tnk-lpd-and-prevention-of-post-transplant-graft-versus-host-disease-100595246",false,"NCT07029958","Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T\u002FNK Lymphoproliferative Disease (EBV-T\u002FNK LPD) and Prevention of Post Transplant Graft-versus-host Disease","Inclusion Criteria:\n\n* Meet the diagnosis of EBV-T\u002FNK lymphoproliferative disease (EBV-T\u002FNK LPD) according to the ICC2022 diagnostic criteria\n* Plan to undergo allogeneic hematopoietic stem cell transplantation (allo HSCT) in our hospital\n* Age ≤ 18 years old\n* Sign informed consent form\n* Meet one of the following conditions (haploid donors must meet one of the above conditions, unrelated donors must meet two of the above conditions): ① donor age≥40 years old; ② The donor source is unrelated donor or haplotype related female or collateral donor (brother sisters, etc.) with ≥ 1 point mismatch; ③ CD3≥4 x 10 \\^ 8\u002Fkg before transplantation; ④ The primary disease is in an HLH (hemophagocytic lymphohistiocytosis) flare or active disease phase; ⑤ ATG (or ATLG (1:2)\u002FALG (1:20) equivalent dose)\\\u003C10mg\u002Fkg\n\nExclusion Criteria:\n\n* The expected survival period for multiple organ failure is no more than 3 months\n* Not signing the informed consent form","ALL","0 Years","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T\u002FNK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of GVHD and have a corresponding impact on other related post-transplant complications such as poor engraftment, thrombotic microvascular disease, early EBV reactivation and relapse.",[26],"EBV-T\u002FNK LPD","RECRUITING","2025-06-12",{"date":30,"type":31},"2025-06-19","ACTUAL",{"date":33,"type":31},"2024-11-12",{"date":35,"type":20},"2029-10-30",{"name":37,"class":38},"Beijing Children's Hospital","OTHER"]